BMS-536924 sensitizes human epithelial ovarian cancer cells to the PARP inhibitor, 3-aminobenzamide

Gynecologic Oncology

Volumn 115, Issue 2, 2009, Pages 193-198

  Beauchamp, Marie Claude ^a,b   Knafo, Ariane ^a,b   Yasmeen, Amber ^a,b   Carboni, Joan M ^c   Gottardis, Marco M ^c   Pollak, Michael N ^b,d   Gotlieb, Walter H ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Epithelial ovarian cancer; IGF; Insulin like growth factor inhibitor; PARP inhibitor

Indexed keywords

3 AMINOBENZAMIDE; ANTINEOPLASTIC AGENT; BMS 536924; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; COLORIMETRY; CYTOTOXICITY; DRUG POTENTIATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN CLEAVAGE; WESTERN BLOTTING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; BENZIMIDAZOLES; CELL LINE, TUMOR; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; HUMANS; ONCOGENE PROTEIN V-AKT; OVARIAN NEOPLASMS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PYRIDONES; RECEPTOR, IGF TYPE 1; RIBOSOMAL PROTEIN S6 KINASES;

EID: 70349751409     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.07.009     Document Type: Article

References (37)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71-96
2. Visintin I., Feng Z., Longton G., Ward D.C., Alvero A.B., Lai Y., et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 14 (2008) 1065-1072
3. Wang Y., Ji Q.S., Mulvihill M., and Pachter J.A. Inhibition of the IGF-I receptor for treatment of cancer. Kinase inhibitors and monoclonal antibodies as alternative approaches. Recent Results Cancer Res 172 (2007) 59-76
4. Brokaw J., Katsaros D., Wiley A., Lu L., Su D., Sochirca O., et al. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 25 (2007) 346-354
5. Hartog H., Wesseling J., Boezen H.M., and van der Graaf W.T. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 43 (2007) 1895-1904
6. Kalli K.R., and Conover C.A. The insulin-like growth factor/insulin system in epithelial ovarian cancer. Front Biosci 8 (2003) d714-d722
7. Gotlieb W.H., Bruchim I., Gu J., Shi Y., Camirand A., Blouin M.J., et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 100 (2006) 389-396
8. Haluska P., Carboni J.M., Loegering D.A., Lee F.Y., Wittman M., Saulnier M.G., et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417. Cancer Res 66 (2006) 362-371
9. Jagtap P., and Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov 4 (2005) 421-440
10. Cepeda V., Fuertes M.A., Castilla J., Alonso C., Quevedo C., Soto M., et al. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Patents Anticancer Drug Discov 1 (2006) 39-53
11. Green D.R., and Reed J.C. Mitochondria and apoptosis. Science 281 (1998) 1309-1312
12. Bryant H.E., Schultz N., Thomas H.D., Parker K.M., Flower D., Lopez E., et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434 (2005) 913-917
13. Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434 (2005) 917-921
14. Edwards S.L., Brough R., Lord C.J., Natrajan R., Vatcheva R., Levine D.A., et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451 (2008) 1111-1115
15. Sakai W., Swisher E.M., Karlan B.Y., Agarwal M.K., Higgins J., Friedman C., et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451 (2008) 1116-1120
16. Beckert S., Farrahi F., Perveen Ghani Q., Aslam R., Scheuenstuhl H., Coerper S., et al. IGF-I-induced VEGF expression in HUVEC involves phosphorylation and inhibition of poly(ADP-ribose)polymerase. Biochem Biophys Res Commun 341 (2006) 67-72
17. Provencher D.M., Lounis H., Champoux L., Tetrault M., Manderson E.N., Wang J.C., et al. Characterization of four novel epithelial ovarian cancer cell lines. In Vitro Cell Dev Biol Anim 36 (2000) 357-361
18. Samouelian V., Maugard C.M., Jolicoeur M., Bertrand R., Arcand S.L., Tonin P.N., et al. Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol 54 (2004) 497-504
19. Ikediobi O.N., Davies H., Bignell G., Edkins S., Stevens C., O'Meara S., et al. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol Cancer Ther 5 (2006) 2606-2612
20. Taniguchi T., Tischkowitz M., Ameziane N., Hodgson S.V., Mathew C.G., Joenje H., et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9 (2003) 568-574
21. Lowry O.H., Rosebrough N.J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 193 (1951) 265-275
22. Olive P.L., and Banath J.P. The comet assay: a method to measure DNA damage in individual cells. Nat Protoc 1 (2006) 23-29
23. Plesca D., Mazumder S., and Almasan A. DNA damage response and apoptosis. Methods Enzymol 446 (2008) 107-122
24. Herzog T.J., and Pothuri B. Ovarian cancer: a focus on management of recurrent disease. Nat Clin Pract Oncol 3 (2006) 604-611
25. Haluska P., Carboni J.M., TenEyck C., Attar R.M., Hou X., Yu C., et al. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924. Mol Cancer Ther 7 (2008) 2589-2598
26. Drew Y., and Calvert H. The potential of PARP inhibitors in genetic breast and ovarian cancers. Ann N Y Acad Sci 1138 (2008) 136-145
27. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009)
28. De Soto J.A., Wang X., Tominaga Y., Wang R.H., Cao L., Qiao W., et al. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. Int J Biol Sci 2 (2006) 179-185
29. Sakamoto-Hojo E.T., and Balajee A.S. Targeting poly (ADP) ribose polymerase I (PARP-1) and PARP-1 interacting proteins for cancer treatment. Anticancer Agents Med Chem 8 (2008) 402-416
30. McCabe N., Lord C.J., Tutt A.N., Martin N.M., Smith G.C., and Ashworth A. BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: an issue of potency. Cancer Biol Ther 4 (2005) 934-936
31. Rodon J., Iniesta M.D., and Papadopoulos K. Development of PARP inhibitors in oncology. Expert Opin Investig Drugs 18 (2009) 31-43
32. Hudelist G., Wagner T., Rosner M., Fink-Retter A., Gschwantler-Kaulich D., Czerwenka K., et al. Intratumoral IGF-I protein expression is selectively upregulated in breast cancer patients with BRCA1/2 mutations. Endocr Relat Cancer 14 (2007) 1053-1062
33. Maor S., Yosepovich A., Papa M.Z., Yarden R.I., Mayer D., Friedman E., et al. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. Cancer Lett 257 (2007) 236-243
34. Xiang T., Ohashi A., Huang Y., Pandita T.K., Ludwig T., Powell S.N., et al. Negative regulation of AKT activation by BRCA1. Cancer Res 68 (2008) 10040-10044
35. Maor S.B., Abramovitch S., Erdos M.R., Brody L.C., and Werner H. BRCA1 suppresses insulin-like growth factor-I receptor promoter activity: potential interaction between BRCA1 and Sp1. Mol Genet Metab 69 (2000) 130-136
36. Sarfstein R., Maor S., Reizner N., Abramovitch S., and Werner H. Transcriptional regulation of the insulin-like growth factor-I receptor gene in breast cancer. Mol Cell Endocrinol 252 (2006) 241-246
37. Wen B., Deutsch E., Marangoni E., Frascona V., Maggiorella L., Abdulkarim B., et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 85 (2001) 2017-2021